Lymphoma
Also known as: DLBCL · Hodgkin lymphoma · non-Hodgkin lymphoma
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2025
National Comprehensive Cancer Network (NCCN) · 2025 · 3.2025
Lymphoma is a broad category, so this record uses the NCCN B-Cell Lymphomas guideline as the single most representative current US guideline. The Insights article published in JNCCN documents the featured updates to the version 3.2025 guideline for follicular lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma. The full NCCN guideline itself is distributed through the NCCN website and requires registration.
- Covers featured updates across follicular lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma. source
- Discusses newer classes including CD3 x CD20 bispecific antibodies and CD19-directed agents in the relapsed or refractory setting. source
- Published in the Journal of the National Comprehensive Cancer Network, volume 23, issue 10 (October 2025). source
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
European Society for Medical Oncology (ESMO) · 2025
A consolidated ESMO guideline that replaces the society's previously separate lymphoma documents, chosen as the single most representative current EU guideline for this broad topic. It covers seven systemic lymphoma types in one document, spanning epidemiology, diagnosis, staging, risk assessment, first-line and relapsed or refractory treatment, and follow-up.
- Covers diffuse large B-cell lymphoma, primary CNS lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Hodgkin lymphoma and nodal peripheral T-cell lymphoma in one guideline. source
- Provides management algorithms alongside recommendations for each disease covered. source
- Published in Annals of Oncology, volume 36, pages 1263-1284 (November 2025), lead author T. A. Eyre. source
US vs EU key differences
- Update cadence differs markedly: NCCN revises its B-Cell Lymphomas guideline several times a year as separately numbered versions (version 3.2025 was followed by version 4.2026 within about a year), while ESMO published its lymphomas guideline as a single consolidated 2025 document. source
- Document structure differs: the ESMO guideline treats several common lymphoma entities together in one publication covering diagnosis, treatment and follow-up, whereas NCCN splits the field by lineage and maintains B-cell lymphomas as its own algorithm set spanning DLBCL, follicular, mantle cell, marginal zone, Burkitt, high-grade and post-transplant lymphoproliferative disorders. source
- Access model differs: NCCN guideline content is licence-restricted and distributed through NCCN's own portal, while the ESMO guideline is published as a journal article in Annals of Oncology. source
What changed recently
- US2.2025 → 3.20252025-10-01
NCCN's published Insights article for this version bump describes the panel's discussion of newly incorporated data in three areas: CD3xCD20 bispecific antibodies and CD19-directed antibodies/antibody-drug conjugates in relapsed or refractory follicular lymphoma, BTK inhibitor-based regimens in TP53-mutated classical mantle cell lymphoma, and bispecific antibodies added to chemoimmunotherapy in relapsed or refractory DLBCL.
source ↗curation confidence 90%
See the full update feed for changes across every system.